Introduction {#sec1}
============

*Citrobacter amalonaticus,* formerly called *Levinea amalonatica,* was first studied and described in 1971 after being isolated from various human samples from hospitalized patients, especially faeces [@bib1]. Since then this bacterial species has been isolated from the environment [@bib2], [@bib3] as well as sporadically isolated from humans, mainly in faecal, urine, wound and respiratory samples [@bib1], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9]. Recently our syndromic clinical laboratory-based surveillance system, called BALYSES (the BActerial real-time LaboratorY-based SurveillancE System) [@bib10], detected two consecutive *C. amalonaticus* kidney infections in two renal transplant recipients hospitalized in the same nephrology unit in Conception Hospital, Marseille, France. An additional two cases of *C. amalonaticus* infection were then detected over the following few weeks at other university hospitals in Marseille. We report here all cases from the literature to date.

Case Reports {#sec2}
============

Case 1 {#sec2.1}
------

A 75-year-old woman with chronic renal failure due to membranoproliferative glomerulonephritis who had received a transplant in December 2010 was admitted to the nephrology unit of Conception Hospital for a regular check of her renal transplant. Since her transplantation the patient had developed membranoproliferative glomerulonephritis in the kidney transplant, urinary tract infections (UTIs) and diabetes as a result of immunosuppressive therapy. At admission in December 2014 analysis of a urine sample revealed leukocyturia (29.8 elements/mm^3^) and bacteriuria (10^4^/mL *C. amalonaticus,* identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF; Bruker Daltonics, Leipzig, Germany)). Antimicrobial susceptibility testing revealed that the isolate was resistant to amoxicillin and susceptible to third-generation cephalosporins, carbapenem, cotrimoxazole, ciprofloxacin and amoxicillin/clavulanate. The patient was treated with amoxicillin/clavulanate during 7 days and was considered cured.

Case 2 {#sec2.2}
------

A 61-year-old man who had received a renal transplant in November 2014 visited the nephrology unit at Conception Hospital for his weekly checkup in December 2014. In the urine samples collected, leukocyturia was 25.2 elements/mm^3^, and bacteriuria was 10^4^/mL with *C. amalonaticus,* which was identified by MALDI-TOF. In this case *C. amalonaticus* was resistant to amoxicillin, ticarcillin and cotrimoxazole and susceptible to amoxicillin/clavulanate, ticarcillin/clavulanate, third-generation cephalosporins, carbapenems, nitrofurantoin, gentamicin and ciprofloxacin. The patient was treated a first time in December with ciprofloxacin during 7 days; antibiotic therapy was recommended only during urologic surgery. He underwent treatment a second time from 11 March 2015 to 3 April 2015.

Case 3 {#sec2.3}
------

A 4-year-old child with Leigh syndrome, which is a mitochondrial cytopathy due to a heterozygote mutation on the *SURF1* gene, was admitted to the intensive care unit at Timone Hospital for cardiogenic shock due to Epstein-Barr virus infection on 16 February 2015. On 6 April 2015 a urine sample was collected; analysis revealed that leukocyturia was 35 elements/mm^3^, hematuria 8 elements/mm^3^ and bacteriuria 10^4^/mL*.* The bacterium *C. amalonaticus,* identified by MALDI-TOF, was resistant to amoxicillin, amoxicillin/clavulanate, ticarcillin and ticarcillin/clavulanate and susceptible to carbapenems, third-generation cephalosporins, carbapenems, nitrofurantoin, ciprofloxacin and cotrimoxazole. The patient was treated with cotrimoxazole and was cured after 7 days of treatment.

Case 4 {#sec2.4}
------

A 27-day-old newborn girl was brought into the paediatric unit in North Hospital on 4 March 2015 for rhinitis and fever (temperature 38.3°C). A urine sample was collected; analysis revealed leukocyturia at 13.2 elements/mm^3^ and bacteriuria 10^7^/mL *C. amalonaticus.* The strain was susceptible to amoxicillin/clavulanate, ticarcillin/clavulanate, ciprofloxacin, cotrimoxazole, nitrofurantoin, carbapenems and third-generation cephalosporins but resistant to amoxicillin and ticarcillin. The patient was symptomatically treated with paracetamol for fever; no antibiotic treatment was provided for asymptomatic urinary colonization.

Epidemiologic features {#sec2.5}
----------------------

Because the two initial cases were reported in the nephrology unit in renal transplant recipients, we looked at our updated 13-year historical database [@bib11] and retrospectively found that 36 patients had experienced *C. amalonaticus* infections before 2015 ([Fig. 1](#fig1){ref-type="fig"}). Most of the infections occurred in male subjects (21 male and 15 female patients), were hospital-acquired infections (22 infections, 62%) and were UTIs (29/36, 80%) ([Fig. 2](#fig2){ref-type="fig"}). We also identified a peak in the number of infected patients in 2012: a total of 12 patients were infected that year ([Fig. 1](#fig1){ref-type="fig"}). When we compared the global number of patients experiencing *C. amalonaticus* UTIs before 2012 and since 2012 to the number of patients experiencing *Escherichia coli* UTIs over the same two time periods, based on our updated 13-year historical database [@bib11], we observed that there were statistically more UTIs due to *C. amalonaticus* after the 2012 peak than before (11 in 25 789 patient--bacteria pairs from 2002 to 2011 vs. 18 of 13 502 patient--bacteria pairs from 2012 to 2014; p 0.003). Moreover, we observed that the majority of the strains were collected from young children (11 patients, 31% of all infected patients). When we compared the proportion of patients experiencing *C. amalonaticus* infection who were younger than 11 years old to that of *E. coli* infection, based on our historical database [@bib11], we noted that the proportion of patients under 11 years infected by *C. amalonaticus* was statistically higher than that of *E. coli* (11 of 6361 patient--bacteria pairs vs. 25 of 43 169 patient--bacteria pairs; p 0.003). Furthermore, we statistically identified more patients infected with *C. amalonaticus* after the introduction of MALDI-TOF technology for routine bacteria identification in our laboratory [@bib11] in 2009 than before (nine of 82 436 patient--bacteria pairs from 2002 to 2008 vs. 27 of 115 922 patient--bacteria pairs from 2009 to 2014; p 0.04) ([Fig. 1](#fig1){ref-type="fig"}).

Discussion {#sec3}
==========

*C. amalonaticus* has only rarely been isolated in humans ([Table 1](#tbl1){ref-type="table"}). In 2009, a Chinese woman who had received a kidney transplant contracted peritonitis due to *C. amalonaticus.* In another study, a 63-year-old woman who had undergone bone marrow transplantation developed wound infection caused by *C. amalonaticus.* Another case concerned a 75-year-old man with pancreatic cancer who contracted a biliary tract infection and bacteraemia due to *C. amalonaticus.* In Italy, it was recovered from a urine sample in one patient who had received a renal graft 10 months earlier. In the United States, between 1972 and 1978, at the Seattle Veterans Administration Medical Center, *C. amalonaticus* was identified in urine and fluid samples from five patients. Among these patients, two had UTIs. In Thailand, a man contracted enteric fever, and *C. amalonaticus* was incriminated.

In our study, we identified four cases of *C. amalonaticus* infection by MALDI-TOF. The four spectra were then included in a dendrogram built with Bruker MALDI Biotyper 3.0 software ([Fig. 3](#fig3){ref-type="fig"}). Among all cases reported, including ours, we observed five patients who had undergone kidney transplantation or who had a urinary tract abnormality (case 6) [@bib7]. Also, we observed that patients were mainly immunocompromised, including a patient with a renal graft [@bib9], [@bib12], a newborn patient (case 4) and patients with leukaemia and pancreatic cancer (cases 2 and 3) [@bib4], [@bib6]. Taken together, our observations and those in previously published reports ([Table 1](#tbl1){ref-type="table"}) lead us to think that this bacterium is an opportunistic pathogen, especially in patients with urinary tract failure. The fact that *C. amalonaticus* infection was rarely reported in the past may be explained by the fact that this bacterium is difficult to identify ([Table 1](#tbl1){ref-type="table"}). Thus, conventional methods such as the API system and RapID onE may underestimate their prevalence by misidentifying the strains [@bib7], [@bib13], [@bib14], [@bib15], [@bib16]. The fact we statistically identified more *C. amalonaticus* infections after we instituted the routine use of the MALDI-TOF may have resulted in an improvement in the identification of this bacterial species. However, we found a statistically higher prevalence of the number of UTIs due to this bacterium even after routine use of MALDI-TOF (after 2012), suggesting that it is likely that this bacteria could be an emerging pathogen responsible for UTIs in immunocompromised patients.
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![Annual evolution of number of patients with *Citrobacter amalonaticus* infections at our hospital from January 2002 to December 2014.](gr1){#fig1}

![Main features of 36 patients with *Citrobacter amalonaticus* infections. (A) Age distribution of patients infected with *C. amalonaticus*. (B) Different kinds of samples from which bacterium was isolated.](gr2){#fig2}

![Main-spectrum dendrogram of four *Citrobacter amalonaticus* isolates built from protein spectra.](gr3){#fig3}

###### 

Characteristics of patients with *Citrobacter amalonaticus* infections reported in our studies and elsewhere[a](#tbl1fna){ref-type="table-fn"}

  Case, no. of patient (country)   Age (years)/sex   Infection type                      Underlying condition                                              Sampling date       Identification method           Antibiotic therapy   Issue   Reference
  -------------------------------- ----------------- ----------------------------------- ----------------------------------------------------------------- ------------------- ------------------------------- -------------------- ------- -----------
  1, 1 (China)                     47/F              Peritonitis                         IgA nephropathy, renal graft, intermittent peritoneal dialysis    NA                  Biochemical tests and16S rRNA   CAZ AK               Cure    [@bib9]
  2, 1 (Italy)                     63/F              Wound infection                     ABMT, AML, intracranial haemorrhages                              NA                  Vitek 2 system                  TG                   Cure    [@bib4]
  3, 1 (Taiwan)                    75/M              Bacteraemia                         Ampulla vater cancer                                              NA                  Phoenix automated system        CMZ                  Cure    [@bib6]
  4, 1 (Italy)                     NA                NA                                  Renal allograft 10 months earlier                                 NA                  API 20E                         NA                   NA      [@bib12]
  5, 1 (Thailand)                  53/M              Enteric fever                       Fever, water diarrhoea, headache, travel to Asia                  NA                  Biochemical tests               CRO SXT              Cure    [@bib8]
  6, 5 (USA)                       2 patients        NA                                  Urinary tract abnormality, diabetes, malignancy                   NA                  Biochemical tests               NA                   NA      [@bib7]
  3 patients                       NA                Diabetes mellitus                   NA                                                                NA                  NA                                                           
  1, 1 (France)                    77/F              Urinary tract infection             Renal graft, chronic nephropathy, diabetes                        02/03/15            MALDI-TOF                       AMC                  Cure    Our study
  2, 1 (France)                    61/M              Urinary tract infection             Renal graft, lymphatic cyst of graft, ureter stenosis, diabetes   10/12/14 04/03/15   MALDI-TOF                       CIP                  Cure    Our study
  3, 1 (France)                    4/M               Urinary tract infection             Leigh syndrome                                                    04/02/15            MALDI-TOF                       SXT                  Cure    Our study
  4, 1 (France)                    0/F               Asymptomatic urinary colonization   Fever, rhinitis                                                   04/03/15            MALDI-TOF                       No                   Cure    Our study

ABMT, allogenic bone marrow transplantation; AMC, amoxicillin/clavulanate; AMT, acute myelogenous leukaemia; CAZ, ceftazidime; CIP, ciprofloxacin; CMZ, cefmetazole; CRO, ceftriaxone; Ig, immunoglobulin; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; NA data not available; SXT, cotrimoxazole; TG, tigecycline.

Case = number of cases previously described in the literature; no of patient = number of patients infected in the case report.

Only studies reporting fully described infections with well-identified *C. amalonaticus* are included.
